Revolution Medicines (NASDAQ:RVMD) Research Coverage Started at Brookline Capital Markets

Brookline Capital Markets started coverage on shares of Revolution Medicines (NASDAQ:RVMD) in a research report sent to investors on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $318.00 price objective on the stock. Brookline Capital Markets also issued estimates for Revolution Medicines’ FY2027 earnings at ($5.00) EPS, FY2028 earnings at $0.94 EPS, FY2029 earnings at $8.94 EPS and FY2030 earnings at $18.15 EPS.

Other analysts have also recently issued research reports about the stock. Guggenheim upped their price target on shares of Revolution Medicines from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Friday, August 28th. Needham & Company LLC lifted their price objective on Revolution Medicines from $240.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday, August 31st. The Goldman Sachs Group began coverage on Revolution Medicines in a research note on Thursday, September 24th. They issued a “buy” rating and a $267.00 price objective on the stock. UBS Group upped their target price on Revolution Medicines from $220.00 to $265.00 and gave the company a “buy” rating in a research report on Friday, August 28th. Finally, Bank of America raised their target price on Revolution Medicines from $225.00 to $265.00 and gave the stock a “buy” rating in a research note on Monday, September 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Revolution Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $234.33.

Revolution Medicines Stock Up 0.4%

Shares of NASDAQ RVMD opened at $205.26 on Monday. The company has a market capitalization of $44.00 billion, a P/E ratio of -23.27 and a beta of 1.40. Revolution Medicines has a 52-week low of $45.60 and a 52-week high of $224.31. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. The company’s 50 day moving average price is $202.11 and its 200-day moving average price is $165.61.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the company earned ($1.31) EPS. Equities analysts forecast that Revolution Medicines will post -8.87 earnings per share for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, COO Margaret Horn sold 4,967 shares of the firm’s stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total value of $989,625.08. Following the completion of the sale, the chief operating officer directly owned 149,680 shares in the company, valued at approximately $29,822,243.20. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 4,053 shares of Revolution Medicines stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the sale, the chief financial officer directly owned 119,216 shares of the company’s stock, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 284,682 shares of company stock valued at $58,147,464. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Revolution Medicines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in Revolution Medicines by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company’s stock worth $980,036,000 after acquiring an additional 947,448 shares in the last quarter. Geode Capital Management LLC grew its stake in Revolution Medicines by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,161,963 shares of the company’s stock valued at $251,912,000 after acquiring an additional 16,323 shares during the period. Alphabet Inc. bought a new stake in shares of Revolution Medicines during the second quarter valued at approximately $551,843,000. Westfield Capital Management Co. LP increased its holdings in shares of Revolution Medicines by 13.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 2,845,013 shares of the company’s stock valued at $226,605,000 after acquiring an additional 331,046 shares in the last quarter. Finally, General Atlantic L.P. increased its holdings in shares of Revolution Medicines by 13.7% during the fourth quarter. General Atlantic L.P. now owns 2,812,928 shares of the company’s stock valued at $224,050,000 after acquiring an additional 338,500 shares in the last quarter. 94.34% of the stock is owned by institutional investors.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for patients with cancer. The company’s research centers on the RAS signaling pathway, a key driver of tumor growth that is altered in many cancers, including those involving KRAS mutations.

Its pipeline includes RAS(ON) inhibitors designed to target active RAS proteins and address a range of RAS-driven tumors. Key development programs include daraxonrasib (RMC-6236), a broad-spectrum RAS inhibitor, and zoldonrasib (RMC-9805), an investigational inhibitor aimed at KRAS G12D-mutated cancers.